Argonaut Manufacturing Services opens custom controls & standards facility
The CMO has designed the new service to alleviate manufacturing challenges associated with positive controls and nucleic acid templates
Argonaut Manufacturing Services, a contract manufacturing organization for Life Science, Diagnostic, and BioPharma markets, has launched a new service offering to support the growing need for custom controls, standards and verification panels.
Formulating and filling these products will be performed at a new standalone facility in Carlsbad, California.
The company said the site has been designed to alleviate many of the concerns expressed with the manufacturing challenges associated with positive controls and nucleic acid templates.
Controls and standards are used regularly by innovators to verify instruments, reagents, and diagnostic tests to ensure standard operating procedures (SOPs) are followed properly for patient samples.
The Custom Molecular Controls and Standards service provides organizations focusing on diagnostics for the regulated markets and RUO (research use only) assays, a complete solution for their commercial products with Argonaut and controls that match the same quality standards that Argonaut Manufacturing Services provides.
“This service offering has been widely requested by our clients in every market from Point of Care device makers to platform companies,” said Wayne Woodard, CEO of Argonaut.
The CMO's new offering provides a wide range of solutions including synthetic PCR controls, antibodies, buffers, and markers. Controls and standards can also be lyophilized to both extend shelf-life and improve protocols.
Rather than being restricted to off-the-shelf controls or putting in the capital equipment and labour-intensive SOPs to manufacture their own controls, clients can quickly add controls that are specific for their assays.
Eric Blair, COO of Argonaut, said that with the company's strength in lyophilization, its Custom Molecular Controls and Standards service offers opportunities for improving assays by reducing waste due to shelf-life issues, and simplifying protocols by reducing pipetting and mixing steps.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance